⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24304219 | 0.76 | — | — | |
| SCHEMBL18745922 | 0.73 | — | — | |
| SCHEMBL16578340 | 0.73 | — | — | |
| SCHEMBL20430709 | 0.73 | — | — | |
| SCHEMBL24113293 | 0.73 | — | — | |
| SCHEMBL21128013 | 0.73 | — | — | |
| SCHEMBL22269047 | 0.71 | — | — | |
| SCHEMBL23325756 | 0.69 | — | — | |
| SCHEMBL18938460 | 0.69 | — | — | |
| SCHEMBL24081584 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-11066391-B1 | Atorvastatin derived HMG-CoA reductase degradation inducing compound | UPPTHERA (KR) | 2021-07-20 | — | — | US | disclosed |
| WO-2021127452-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20170209460-A1 | COMPOSITIONS AND METHODS FOR TREATING DENGUE VIRUS INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-07-27 | — | — | US | disclosed |
| US-20170204055-A1 | INHIBITORS OF DEUBIQUITINATING PROTEASES | BRANDEIS UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-9708370-B2 | Azapeptides as CD36 binding compounds | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2017-07-18 | — | — | US | disclosed |
| US-9695205-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| US-20100221261-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-09-02 | — | — | US | disclosed |
| US-20100210566-A1 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-08-19 | — | — | US | disclosed |
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-08-12 | — | — | US | disclosed |
| US-20100204280-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | UNIVERSITE DE MONTREAL (CA) | 2010-08-12 | — | — | US | disclosed |
| US-7645741-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | AEGERA THERAPEUTICS, INC. | 2010-01-12 | — | — | US | disclosed |
| US-7579320-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-08-25 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-7521425-B2 | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-21 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |